The development of robust, optimized manufacturing processes early in process development is essential to enable future scale-up of therapeutic MSCs to clinically-relevant volumes. This application note describes using an efficient DOE approach to process optimization in a scale-down model.

Read to learn about:

• Screening several process parameters simultaneously in multi-parallel bioreactors with real-time monitoring of CPPs
  
• Generating process insight through MVDA correlation of CPPs and CQAs
• Setting design space for successful future scale-up